Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 2,469 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ovarian Cancer Clear all

Conditions: Ovarian Cancer
Interventions: Topotecan; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Platinum-resistant Epithelial Ovarian Cancer
Interventions: Maveropepimut-S, Cyclophosphamide 50mg; Other · Drug
Lead sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Palo Alto, California • Ocala, Florida • Mineola, New York + 1 more

Conditions: Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
Interventions: cabozantinib, atezolizumab; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 914 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 57
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more

Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
Interventions: NM1F Injection, Pembrolizumab injection; Drug
Lead sponsor: Hefei TG ImmunoPharma Co., Ltd.; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Dallas, Texas • Fairfax, Virginia

Conditions: Neoplasms, Triple Negative Breast Cancer, Ovarian Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: niraparib, pembrolizumab; Drug · Biological
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more

Conditions: Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma, Lung Adenocarcinoma, Bladder Urothelial Carcinoma, Stomach Adenocarcinoma, Breast Cancer Invasive, Ovarian Carcinoma, Cervical Cancer, Non Small Cell Lung Cancer, Gastric Cancer, Biliary Tract Cancer, Melanoma, Pancreas Cancer, MDM2 Gene Amplification, Testicular Germ Cell Tumor, Adrenocortical Carcinoma
Interventions: RAIN-32; Drug
Lead sponsor: Rain Oncology Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 14
States / cities: Palo Alto, California • Fort Myers, Florida • St. Petersburg, Florida + 10 more

Conditions: Primary Peritoneal Cancer, Advanced Epithelial Ovarian Cancer
Interventions: Iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Polycystic Ovary Syndrome
Interventions: 3 mg DRSP/20 μg EE; Drug
Lead sponsor: Woman's; Other
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Ovarian Cancer
Interventions: PDS (Primary Debulkdung Surgery), 6 cycles of standard chemotherapy, Timing of surgery after 3 cycles of standard NACT, IDS, IDS, 3 cycles of standard chemotherapy; Procedure · Drug
Lead sponsor: AGO Study Group; Other
Eligibility: 18 Years and older · Female only
Enrollment: 797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Interventions: Adavosertib, Paclitaxel, Carboplatin, Gemcitabine, PLD; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 18
States / cities: Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 14 more

Conditions: Recurrent Ovarian Cancer
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions: cediranib maleate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 21
States / cities: Duarte, California • Los Angeles, California • Pasadena, California + 17 more

Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Bevacizumab, Fosbretabulin Tromethamine, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 51
States / cities: Phoenix, Arizona • Burbank, California • Concord, California + 40 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions: Autologous Monocytes + ACTIMMUNE + SYLATRON; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer, Merkel Cell Carcinoma, SCLC
Interventions: BB-10901; Drug
Lead sponsor: ImmunoGen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Las Vegas, Nevada • Columbus, Ohio + 3 more

Conditions: Ovarian Neoplasms
Interventions: Anetumab ravtansine (BAY94-9343), Pegylated Liposomal Doxorubicin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Aurora, Colorado • New Haven, Connecticut • Oklahoma City, Oklahoma

Conditions: Obesity, Hyperlipidemias, Polycystic Ovary Syndrome, Hypertension, Coronary Heart Disease, Heart Failure, Depression, Anxiety, Type II Diabetes, Metabolic Syndrome
Interventions: Lifestyle counseling and coaching; Behavioral
Lead sponsor: West Virginia School of Osteopathic Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Lewisburg, West Virginia

Conditions: Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Interventions: Laboratory Biomarker Analysis, Sorafenib Tosylate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ovarian Tumor
Interventions: Blood Draw; Procedure
Lead sponsor: Ciphergen Biosystems; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 18
States / cities: Hoover, Alabama • Phoenix, Arizona • Newport Beach, California + 14 more

Conditions: Advanced Malignant Solid Neoplasm, Ovarian Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma
Interventions: Mivavotinib, Paclitaxel, Pharmacokinetic Study; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Polycystic Ovary Syndrome, Menopause
Interventions: Not listed
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Letrozole; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC)
Interventions: EXS74539; Drug
Lead sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Los Angeles, California • Fort Worth, Texas • West Valley City, Utah

Search by objective public record fields.

Weekly Topotecan Therapy in Patients With Ovarian Cancer

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Familial Investigations of Childhood Cancer Predisposition

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

Milademetan in Advanced/Metastatic Solid Tumors

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism

Trial on Radical Upfront Surgery in Advanced Ovarian Cancer

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients

Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Assess Cancer in Ovarian Tumors With Biomarkers.

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

Health Risks and Barriers to Management Across the PCOS Lifespan

Letrozole in Patients With Ovarian Tumors

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors